X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MIN-101 (roluperidone) has been shown to block serotonin, sigma and α-adrenergic receptors that are all involved in the regulation of important brain functions. It is being evaluated for the treatment of negative symptoms in patients with schizophrenia.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
Minerva intends to use the net proceeds to support potential regulatory approval in the U.S., commercialization activities and market launch of MIN-101 (roluperidone), which is being developed for the treatment of negative symptoms in schizophrenia.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 28, 2023
Details:
MIN-101 (roluperidone) is an investigational drug that has been shown to block serotonin, sigma and α-adrenergic receptors that are all involved in the regulation of important brain functions, including mood, cognition, sleep, and anxiety.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
MIN-101 (roluperidone) is a compound that has been shown to block serotonin, sigma and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. It is being developed to treat the negative symptoms of patients with schizophrenia.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
Roluperidone (MIN-101) has been designed to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation and thought and movement disorders.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
The MIN-101 (roluperidone) clinical development program aims to provide effective treatment for negative symptoms of schizophrenia, a significant unmet medical need in a large patient population.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
MIN-101 (roluperidone) is a compound that has been shown to block serotonin, sigma and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety to treat negative symptoms of patients with schizophrenia.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
Roluperidone at both doses was safe and well tolerated, and treatment-emergent adverse events (TEAE) were generally mild to moderate in severity.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
Royalty Pharma will acquire Minerva’s royalty interest in seltorexant. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.
Lead Product(s): Seltorexant
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-202
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $155.0 million Upfront Cash: $60.0 million
Deal Type: Acquisition January 19, 2021
Details:
The objective of this meeting was to obtain FDA input regarding the roluperidone data package and its readiness to support a New Drug Application (NDA) submission.
Lead Product(s): Roluperidone
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
